home / stock / phat / phat news

PHAT News and Press, Phathom Pharmaceuticals Inc. From 10/23/22

Stock Information
Company Name: Phathom Pharmaceuticals Inc.
Stock Symbol: PHAT
Market: NYSE
Website: phathompharma.com
Menu
PHAT PHAT Quote PHAT Short PHAT News PHAT Articles PHAT Message Board
Get PHAT Alerts

News, Short Squeeze, Breakout and More Instantly...
PHAT - Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an investigation...
PHAT - Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today the company will present new data and resea...

PHAT - Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie...

PHAT - Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will p...
PHAT - PHAT and SKYX among mid-day movers

Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...

PHAT - FTAI, UTME and CMRA among mid-day movers

Gainers: AMTD IDEA ( AMTD ) +350% . AMTD Digital ( HKD ) +96% . Ostin Technology Group ( OST ) +67% . 36Kr Holdings ( KRKR ) +60% . Intelligent Living ( ILAG ) +41% . Liberty TripAdvisor ( LTRPB ) +40% . United Ti...

PHAT - Quoin, Context top healthcare gainers; Ontrak, Phathom lead losers' pack

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...
PHAT - Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$1.33 misses by $0.30 . Net loss for the Q2 2022 was $50.9M. For further details see: Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

PHAT - Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023; if approved, targeting U.S. launch in Q1 2023 VOQUEZNA DUAL and TRIPLE PAK approved by FDA for treat...

PHAT - The Prognosis For Phathom Pharmaceuticals

Today, we put Phathom Pharmaceuticals in the spotlight for the first time. The company just got one FDA approval and is in the process of garnering another for its primary drug candidate vonoprazan. The drug is licensed from Takeda and has seen impressive sales in Japan. An i...
Previous 10 Next 10